Integrating CRISPR-Cas Technology into Organic Electronics for Rapid Point-of-Care Genotyping

将 CRISPR-Cas 技术集成到有机电子器件中以实现快速护理点基因分型

• 批准号: BB/X003442/1
• 负责人: William Newman
• 金额: $ 20.6万
• 依托单位: University of Manchester
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FX003442%2F1
• 关键词: Integrating; CRISPR; Cas; Technology; into

This proposal aims to address a critical unmet need in the treatment of infections in newborn babies. Gentamicin is an antibiotic that is effective in the treatment of a wide range of infections and is used in 100,000 babies per year. This treatment is required in the first hour, "the golden hour" of a baby being seen in the intensive care unit. However, 1 in 500 babies carry a change in their RNR1 gene that predisposes them to complete and irreversible deafness. Genetic testing for this change takes a minimum of two days and so a result is not available in time to prevent the hearing loss in these babies by allowing use of a different antibiotic.In 2020, our team developed the world's first point of care genetic test that can be carried out at the baby's bedside. This test takes 26 minutes and allows safe use of the antibiotic. In a recent study, we showed that the test worked by preventing deafness in three babies and by not delaying antibiotic treatment. Despite the success of this system, we need to develop a different system that is quicker to ensure that there are no delays to effective treatment. As such, there is a clear unmet need for new technological solutions to deliver even more rapid point-of-care genetic testing this is called the Research Problem.In this study, we propose to develop a novel, rapid point-of-care device that is capable of detecting changes in the RNR1 gene more quickly than the current approach. This device will combine a novel gene recognition technology with an organic electronic device platform that is capable of rapid (< 1 min) electronic readout of the gene change of interest. We call this the Research Solution. This research will develop the electronic device and test it with DNA from cheek swab samples, to show that it can be used with human samples.Overall, this proposal aims to develop a next generation diagnostic tool that could support the implementation of rapid genetic testing in mainstream clinical practice, improving outcomes for patients and the healthcare system. Indeed, the device that we propose to develop here could be used for the testing other gene changes important in human health, where a result is required rapidly.

该提案旨在解决新生儿感染治疗方面尚未满足的关键需求。庆大霉素是一种抗生素，可有效治疗各种感染，每年有10万名婴儿使用。这种治疗需要在第一个小时，“黄金时间”的婴儿被看到在重症监护室。然而，每500个婴儿中就有1个携带RNR 1基因的变化，使他们容易患上完全和不可逆的耳聋。针对这一变化的基因检测至少需要两天时间，因此无法及时获得结果，以通过允许使用不同的抗生素来预防这些婴儿的听力损失。2020年，我们的团队开发了世界上第一个可以在婴儿床边进行的护理点基因检测。该测试需要26分钟，并允许安全使用抗生素。在最近的一项研究中，我们表明，该测试通过预防三名婴儿的耳聋而起作用，并且不会延迟抗生素治疗。尽管这一系统取得了成功，但我们需要开发一个更快的不同系统，以确保有效治疗不会出现延误。因此，有一个明确的未满足的需要，新的技术解决方案，提供更快速的床旁基因检测这是所谓的研究Problem.在这项研究中，我们建议开发一种新的，快速床旁设备，能够检测到的变化，在RNR 1基因比目前的方法更快。该装置将联合收割机与有机电子装置平台结合，该有机电子装置平台能够快速（< 1分钟）电子读出感兴趣的基因变化。我们称之为研究解决方案。这项研究将开发电子设备，并使用颊拭子样本的DNA进行测试，以证明它可以用于人类样本。总的来说，这项提案旨在开发下一代诊断工具，可以支持在主流临床实践中实施快速基因检测，改善患者和医疗保健系统的结果。事实上，我们在这里提议开发的设备可以用于测试对人类健康重要的其他基因变化，这些变化需要快速得到结果。